Selection of blockbuster announcements

1 、$Tencent (00700.HK) $Q1's revenue is 135.471 billion yuan, which is the same as the same period last year

Tencent announced the results for the first quarter ended March 31, 2022. The financial report shows that Q1's revenue is 135.471 billion yuan, compared with 135.303 billion yuan in the same period last year, which is the same as the same period last year; net profit is 23.413 billion yuan, down 51% from the same period last year; adjusted net profit is 25.545 billion yuan, down 23% from the same period last year; diluted earnings per share are 2.404 yuan, compared with 4.917 yuan in the same period last year.

2 、$GDS Holdings Limited-SW (09698.HK) $Q1 net income increased by 31.5% to 2.243 billion yuan compared with the same period last year

GDS Holdings Limited-SW releases first-quarter results. The company's net income was 2.243 billion yuan (the same as the same unit below), up 31.5% over the same period last year; gross profit was 486 million yuan, up 22.6% over the same period last year; and the basic loss per share was 0.39 yuan.

3 、$Yasheng Pharmaceutical-B (06855.HK) $Orebatinib, an original class 1 new drug, has the potential to treat COVID-19

Yasheng Pharmaceutical announced on the evening of May 18th that a new preclinical study conducted by researchers at Fred Hutchinson Cancer Research Center in Seattle found that Orebatinib (Nerek ®) has the potential to treat cytokine storms induced by novel coronavirus mutant Omicron. The research results were published in the famous international journal EMBO Molecular Medicine on May 18th.

4 、$Fuhong Hanlin (02696.HK) $Phase 3 clinical study of Hans-like ®combined with chemotherapy in the treatment of locally advanced ╱ metastatic esophageal squamous cell carcinoma reached the main end point.

Fuhong Hanlin announced that recently, a phase 3 clinical study comparing the company's self-developed Hans-like ®(Srelizumab injection) or placebo combined chemotherapy (cisplatin + 5-FU) in the treatment of locally advanced ╱ metastatic esophageal squamous cell carcinoma (ESCC) patients in the planned mid-term analysis, the independent data monitoring committee evaluated the dual major study endpoints of progression-free survival (PFS) and overall survival (OS).

5 、$Guangdong Investment (00270.HK) $Join hands with Feilaixia hydropower to build a number of distributed photovoltaic power station projects

Guangdong Investment announced that in order to support and promote the development of green and clean new energy and China's strategic goal of "carbon peak and carbon neutralization", on May 18, 2022, Guangdong Water (a wholly-owned subsidiary of the company) and Feilaixia Hydropower (a wholly-owned subsidiary of Guangdong Holdings) entered into a cooperative project to build a number of distributed photovoltaic power stations. The generated electricity is supplied (including) the photovoltaic power generation framework agreement for the self-use of Guangdong Water Group for a period of three years.

Financial data

Tencent (00700): Q1 has revenue of 135.471 billion yuan, which is the same as the same period last year.

GDS Holdings Limited-SW (09698): net income in the first quarter increased by 31.5% year on year to 2.24 billion yuan

Sany International (00631) first quarter revenue of 4.116 billion yuan robot business increased 105%

Operation data

China Coal Energy (01898): commercial coal sales of 22.82 million tons fell 19.2% in April compared with the same period last year.

Value Management Group (00806): total assets under management at the end of April were $7.9 billion

Investment and operation

Guangdong Investment (00270) joined hands with Feilaixia Hydropower Station to build a number of distributed photovoltaic power stations.

Fu Hong Hanlin (02696): phase 3 clinical study of Hans-like ®combined with chemotherapy in the treatment of locally advanced ╱ metastatic esophageal squamous cell carcinoma reached the end point.

Yasheng Pharmaceutical-B (06855): preclinical data show that Orebatinib has the potential to treat COVID-19

Jiahe Bio-B (06998): the first human clinical trial of GB263T completes the first patient administration.

Sino Biopharmaceutical (01177) signs an agreement to purchase monoclonal antibodies against LAG3

CSPC Pharmaceutical (01093): "doxophylline injection" was approved by drug registration.

Genscript Biotech Corporation (01548): eight abstracts of the bid study have been selected for the 2022 ASCO Annual meeting and the 2022 EHA online and offline mixed Conference.

China ship Leasing (03877) sets up a joint venture company to acquire and operate ships

Repurchase cancellation

Standard Chartered PLC (02888) spent 11.828 million pounds to buy back 1.99 million shares on May 17.

AIA Group Limited (01299) spent HK $39.331 million to buy back 507600 shares on May 18.

Haier Smart Home (06690) spent 51.2179 million yuan to buy back 2 million A shares on May 18.

Guotai Junan International (01788) spent HK $1.223 million to buy back 1.43 million shares on May 18.

Equity incentive

Huayi Tencent Entertainment (00419) awarded a total of 77.5 million award shares

Sino Biopharmaceutical (01177): the trustee further purchased 10 million shares

Weitai Medical-B (02235) proposes to adopt the 2022 H-share Award Trust Scheme